Silver Book Fact

A medicine is in development that aims to prevent or reverse Alzheimer’s disease progression by using a human monoclonal antibody specifically designed to remove beta amyloid protein from the brain.

PhRMA. 2008 Report: Medicines in Development for Older Americans; November 2008

Reference

Title
2008 Report: Medicines in Development for Older Americans
Publication Date
November 2008
Authors
PhRMA

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • One study found that dopaminergenic therapies for Parkinson’s disease patients resulted in lower dyskinesias as well as lower incidences of freezing, drowsiness, and edema–resulting in better quality-of-life through symptom control.  
  • Delaying the onset and progression of Alzheimer’s disease would reduce the projected number of people with moderate to severe cases of the disase to 4.4 million instead of 10.3 million…  
  • “If you or a loved one started exhibiting symptoms of Alzheimer’s disease 12 years ago, there were no medicines for you to take. All you could do was hope–that…  
  • Impact of a 5-Year Delay in Onset by Stage of Disease, Americans Age 65 and Older with Alzheimer’s Disease, 2050  
  • A medicine is in development that aims to prevent or reverse Alzheimer’s disease progression by using a human monoclonal antibody specifically designed to remove beta amyloid protein from the brain.